Clinical Trials Browser

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07112053 2026-04-06

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

148 enrolled

Gynecologic

Endometrial Neoplasms

NCT05735080 2026-04-01

INX-315-01

Phase 1/2 Recruiting

150 enrolled

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06365788 2026-04-01

ABBICAR

Phase 2 Recruiting

53 enrolled

Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

Recruiting

3,250 enrolled

Breast

Breast Neoplasms

NCT04791384 2026-03-31

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast

Breast Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Phase 2 Recruiting

105 enrolled

Tumor-Agnostic

Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3 Not yet recruiting

1,056 enrolled

Breast

HR+/HER2- Breast Cancer

Clinical Trials

SERENA-6

ELAINEIII

MoonROSE

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

CAPItello-292

PIKASSO-01

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

FAIM

EvoPAR-BR01

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

UPLIFT

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

EVOLVE-BDT

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

CYCAD-1

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

ELECTRA

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

TAPUR

EndoMAP

INX-315-01

ABBICAR

CAROLEEN

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

CAMPFIRE

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease